Pieris Progresses Proprietary Asthma Program: Validation of
Pulmonary Delivery of Anticalin-Based Protein Product Candidate
FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ --
Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, today announcedsignificant progress in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietaryPRS-060 Anticalin(R) candidate, the Company reports that theprotei...
Pieris Progresses Development of its Proprietary Biotherapeutics
Platform: Successful Demonstration of Dual Targeting With
Duocalin(R) Technology
FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ --
Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, announced todaythat its proprietary Duocalin(R) technology has successfullydemonstrated dual targeting potential. Commenting on this development, Dr Andreas Hohlbaum, Director ofScience and Preclinical D...
Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific
Anticalin in Preclinical Studies
FREISING-WEIHENSTEPHAN, Germany, March 29, 2007 /PRNewswire/ --
Pieris AG, a bio-pharmaceutical company developing therapeuticproducts comprising of Anticalins(R), a novel proprietary class ofhuman binding proteins, announced today it has demonstrated potentanti-tumor activity of PRS-050. The positive results with PRS-050,a VEGF-specific Anticalin(R) with extended serum half life, wereach...